127 related articles for article (PubMed ID: 6895717)
1. Phase II trial of AMSA in refractory breast cancer.
De Lena M; Rossi A; Bonadonna G
Cancer Treat Rep; 1982 Feb; 66(2):403-4. PubMed ID: 6895717
[No Abstract] [Full Text] [Related]
2. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer.
Tannir N; Spitzer G; Schell F; Legha S; Zander A; Blumenschein G
Cancer Treat Rep; 1983 Jun; 67(6):599-600. PubMed ID: 6344995
[No Abstract] [Full Text] [Related]
3. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Amrein PC; Coleman M; Richards F; Poulin RF; Bernhardt B; Ginsberg SJ; Green MR; Morrison A; Cortes E; Kiang D; Weinberg V; Wood WC
Cancer Treat Rep; 1982 May; 66(5):1211-3. PubMed ID: 6896294
[No Abstract] [Full Text] [Related]
5. Phase II trial of amsacrine (AMSA) in urinary bladder cancer.
Natale RB; Yagoda A; Blumenreich MS; Watson RC
Cancer Treat Rep; 1983 Apr; 67(4):391-2. PubMed ID: 6687836
[No Abstract] [Full Text] [Related]
6. Phase II trial of AMSA in prostatic cancer.
Natale RB; Yagofa A; Watson RC
Cancer Treat Rep; 1982 Jan; 66(1):208-9. PubMed ID: 6895482
[No Abstract] [Full Text] [Related]
7. Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung.
Fuks JZ; Van Echo DA; Aisner J; Von Hoff D; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):133-4. PubMed ID: 6261947
[No Abstract] [Full Text] [Related]
8. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
Schneider RJ; Woodcock TM; Yagoda A
Cancer Treat Rep; 1980 Jan; 64(1):183-5. PubMed ID: 6892892
[No Abstract] [Full Text] [Related]
9. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Bonomi P; Blessing JA; Sedlacek TV; Homesley HD; DiSaia PJ
Cancer Treat Rep; 1983 Feb; 67(2):197-8. PubMed ID: 6687445
[No Abstract] [Full Text] [Related]
10. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
11. A phase II trial of m-AMSA in patients with small-cell lung cancer.
Natale RB; Gralla RJ; Wittes RE
Cancer Clin Trials; 1981; 4(4):393-5. PubMed ID: 6274533
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of AMSA in refractory testicular cancer.
Williams SD; Duncan P; Einhorn LH
Cancer Treat Rep; 1983 Mar; 67(3):309-10. PubMed ID: 6687560
[No Abstract] [Full Text] [Related]
13. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.
Amrein PC; Richards F; Coleman M; Poulin RF; Holland JF; Weinberg V; Perry M
Cancer Treat Rep; 1984 Jun; 68(6):923-4. PubMed ID: 6329510
[No Abstract] [Full Text] [Related]
14. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
15. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.
Bukowski RM; Legha S; Saiki J; Eyre HJ; O'Bryan R
Cancer Treat Rep; 1982 Aug; 66(8):1651-2. PubMed ID: 6286120
[TBL] [Abstract][Full Text] [Related]
17. M-AMSA in disseminated prostatic carcinoma: a phase II study.
Drelichman A; Decker DA; Al-Sarraf M; Dhabuwala CB
Cancer Treat Rep; 1982 Nov; 66(11):1993-4. PubMed ID: 6897206
[No Abstract] [Full Text] [Related]
18. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
Sordillo PP; Magill GB; Gralla RJ; Golbey RB
Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
[No Abstract] [Full Text] [Related]
19. Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and leukemia group B phase II study.
Amrein PC; Coleman M; Richards F; Bhardwaj S; Kennedy BJ; Haurani FI; Frelick RW; Pastmantier MW; Herschkopf R
Cancer Treat Rep; 1984 Nov; 68(11):1397-8. PubMed ID: 6548660
[No Abstract] [Full Text] [Related]
20. Phase II study of AMSA in patients with advanced ovarian cancer.
Kearsley JH; Coates AS; Fox RM; Tattersall MH; Page J; Levi JA
Cancer Treat Rep; 1982 May; 66(5):1242-3. PubMed ID: 6896295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
